This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Vifor Pharma Gestion

Gestion contrôle des critères 2/4

Informations clés

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	no data
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	6.9yrs
Durée moyenne du mandat des membres du conseil d'administration	3.6yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Vifor Pharma n'a pas de PDG, ou nous n'avons pas de données sur eux.

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Alexandros Sigalas	Acting CFO & Head of IT & Administration	6.9yrs	pas de données	pas de données
Frederic Zwahlen	Head of Technical Operations	less than a year	pas de données	pas de données
Julien Vignot	Head of Investor Relations & Treasury	5.9yrs	pas de données	pas de données
Oliver Kronenberg	Group General Counsel	8.9yrs	pas de données	pas de données
Nathalie Ponnier	Global Head Corporate Communications	no data	pas de données	pas de données
Michael Puri	Chief Human Resources Officer	7.6yrs	pas de données	0.014% CHF 1.5m
Christoph Springer	Chief Strategy Officer	6.9yrs	pas de données	0.052% CHF 5.6m
Thomas Kaspar	Head of Global Quality Management	11.9yrs	pas de données	pas de données
Thierry Teil	Head of Global Medical Affairs	6.9yrs	pas de données	pas de données
Carolina Ponchione	Head of Executive Search & Employer Branding	4.9yrs	pas de données	pas de données
Barbara Angehrn	Chief Business Officer	4.1yrs	pas de données	0.0027% CHF 290.0k
Antonio Jordao	Regional Head of Southern Europe	no data	pas de données	pas de données

6.9yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Gestion expérimentée: 0RPD's management team is seasoned and experienced (6.9 years average tenure).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Jacques Theurillat	Independent Chairman of the Board	4.6yrs	CHF 1.20m	0.0066% CHF 714.8k
Asa Riisberg	Independent Director	1.6yrs	CHF 133.00k	pas de données
Etienne Jornod	Honorary Chairman	2.6yrs	CHF 3.33m	pas de données
Alexandre Lebeaut	Independent Director	1.6yrs	CHF 117.00k	pas de données
Michel Burnier	Independent Director	12.9yrs	CHF 231.00k	0.017% CHF 1.8m
Romeo Cerutti	Independent Vice Chairman & Lead Independent Director	7.9yrs	CHF 326.00k	0.015% CHF 1.6m
Kim Stratton	Independent Director	3.6yrs	CHF 211.00k	0.0019% CHF 200.5k
Susan Mahony	Independent Director	3.6yrs	CHF 260.00k	0.0022% CHF 236.1k

3.6yrs

Durée moyenne de l'emploi

61.5yo

Âge moyen

Conseil d'administration expérimenté: 0RPD's board of directors are considered experienced (3.6 years average tenure).

This company listing is no longer active

Vifor Pharma Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

High number of new directors

Vifor Pharma Group Appoints Two New Members to the Executive Committee

Vifor Pharma Announces Board Changes

Recent updates

Cancellation of Remaining Publicly Held Registered Shares of Vifor Pharma

Vifor Pharma AG Common Shares to Be Deleted from OTC Equity

SIX Exchange Regulation Approves Delisting of Vifor Pharma AG's Registered Shares

CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.

Vifor Pharma AG(SWX:VIFNE) dropped from FTSE All-World Index (USD)

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Vifor Pharma Ag Approves Dividend, Will Be Paid to Shareholders from 3 May 2022

Vifor Pharma Ag Announces Full Results from Its Phase-IIIb Diamond Trial

Vifor Pharma AG(SWX:VIFN) dropped from Swiss Performance Index (Price Return)

High number of new directors

CSL Plans to Pursue an Application to SIX Exchange Regulation for the Delisting of the Vifor Pharma Shares

Vifor Pharma Group Appoints Two New Members to the Executive Committee

Vifor Pharma Reports Positive Outcome of the Phase-IIIb Diamond Trial of Veltassa®

Vifor Pharma and American Regent Announce Settlement Agreements with Mylan Laboratories Ltd., and Sandoz, Inc., of Injectafer Patent Litigation

Corden Pharma International Gmbh agreed to acquire Finished Drug Product Manufacturing Business of Vifor Pharma Group.

Vifor Pharma and CSL Confirm Merger Talks

Vifor Pharma AG Announces Enrolmenet of First Patient in Phase-IIa Study of Vamifeport in Patients with Sickle Cell Disease

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Investor sentiment improved over the past week

Vifor Says Regularly in Talks with Other Market Participants After Reports

Vifor Pharma AG (SWX:VIFN) entered into a definitive agreement to acquire Sanifit Therapeutics S.A. from group of investor for €375 million.

Cara Therapeutics and Vifor Pharma Announce U.S. FDA Approval of Korsuva™ (Difelikefalin) Injection for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Chief Executive Officer Stefan Schulze has left the company

Vifor Pharma Group Provides Earnings Guidance for the Year 2021

Vifor Pharma to Revise DIAMOND Study

Independent Director has left the company

Independent Director has left the company

Vifor Pharma AG Approves Dividend, Payable from 12 May 2021

Upcoming dividend of CHF2.00 per share

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Cara Therapeutics and Vifor Pharma Group Announce U.S. FDA Acceptance and Priority Review of NDA for KORSUVA™ Injection in Hemodialysis Patients with Moderate-To-Severe Pruritus

Revenue misses expectations

Vifor Pharma AG Provides Phase-II Clinical Trial of VIT-2763 in Non-Transfusion-Dependent Beta-Thalassemia Is Expected to Be Completed in the Second Half of 2021

New 90-day low: CHF113

New 90-day low: CHF118

Vifor Pharma Announces Board Changes

New 90-day high: CHF137

Vifor Pharma Presents the Full Results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress

Market bids up stock over the past week

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

New 90-day low: CHF120

New 90-day low: CHF122

Optimus Holding Ltd. completed the acquisition of OM Pharma SA from Vifor Pharma AG (SWX:VIFN).

Vifor Pharma Announces Outcome of AFFIRM-AHF Topline Data

New 90-day low - CHF124

Vifor Pharma AG to Report First Half, 2021 Results on Jul 28, 2021

First half earnings released

New 90-day low - CHF134

PDG

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen